Press release
Rising Occurrence Of Hepatocellular Carcinoma Fuels Growth In The Hepatocellular Carcinoma Drug Market: Key Factor Driving The Growth In The Hepatocellular Carcinoma Drugs Market
Hepatocellular Carcinoma Drugs
What Is the Expected Hepatocellular Carcinoma Drugs Market Size During the Forecast Period?
The Hepatocellular Carcinoma Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Hepatocellular Carcinoma Drugs Market Size During the Forecast Period?
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10809
What Are the High-Growth Segments in the Hepatocellular Carcinoma Drugs Market?
The hepatocellular carcinoma drugs market covered in this report is segmented -
1) By Type: Brachytherapy, Chemotherapy
2) By Drug Class: PD-1/PD-L1 Inhibitors, Tyrosine Kinase Inhibitors
3) By End User: Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgical Centers
Subsegments:
1) By Brachytherapy: Radioactive Seed Implants, Balloon-Activated Brachytherapy, SIRT (Selective Internal Radiation Therapy)
2) By Chemotherapy: Systemic Chemotherapy, Targeted Therapy Agents, Combination Chemotherapy Regimens, Adjuvant Chemotherapy
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10809&type=smp
What Key Drivers Are Expected to Influence Future Hepatocellular Carcinoma Drugs Market Growth?
The hepatocellular carcinoma drug market is anticipated to flourish due to the increasing incidence of hepatocellular carcinoma in the upcoming years. Hepatocellular carcinoma (HCC) is primarily a malignant liver disease, making it the most prevalent type of liver cancer. The disease takes its origins from the primary liver cells, known as hepatocytes. Mostly, infections from hepatitis B or C, or cirrhosis, are responsible for HCC cases. With the increasing number of hepatocellular carcinoma cases, there is a rising demand for potent hepatocellular carcinoma drugs to combat the disease. For instance, as stated in a report by the American Cancer Society, Inc., a nationwide health organization in the United States aiming at eliminating cancer, estimated that the cases of liver cancer in women diagnosed in the United States rose from 12,660 in 2022 to 13,230 in 2023. Consequently, the surge in hepatocellular carcinoma incidence is fostering the expansion of the hepatocellular carcinoma drug market.
Which Companies Hold the Largest Share Across Different Hepatocellular Carcinoma Drugs Market Segments?
Major companies operating in the hepatocellular carcinoma drugs market include AbbVie Inc., Amgen Inc., Bayer AG, Bristol-Myers Squibb Company, Eisai Co.Ltd., Eli Lilly and Company, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, Gilead Sciences Inc., Exelixis Inc., Ipsen Pharma Biotech SAS, AstraZeneca plc, BeiGene Ltd., Ono Pharmaceutical Co. Ltd., Roche Holdings AG, Sanofi S.A., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hengrui Medicine Co. Ltd., CSPC Pharmaceutical Group Limited, Hutchison China MediTech Limited, Jiangsu Hengrui Medicine Co. Ltd.
What Trends Are Driving Growth in The Hepatocellular Carcinoma Drugs Market?
Major firms in the hepatocellular carcinoma drugs market, such as AstraZeneca PLC, are engineering molecules like monoclonal antibodies (mAb) in laboratories to broaden their customer reach, increase sales and enhance revenue. These laboratory-generated molecules mimic our immune system's functionality of combating harmful substances like bacteria or viruses. Imfinzi (durvalumab) and Imjudo (tremelimumab), both AstraZeneca products accepted by the US FDA in October 2022, are examples of these advances. Imfinzi is a unique human monoclonal antibody that binds to the PD-L1 protein, disrupting the tumor's ability to evade the immune system, thereby enhancing immune response. On the other hand, Imjudo is a specifically designed mAb that targets the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). It stimulates T-cell activation and motivates cancer cells' death by hindering CTLA-4 activity, thus heightening the immune response against cancer.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/hepatocellular-carcinoma-drugs-global-market-report
What Are the Emerging Geographies for The Hepatocellular Carcinoma Drugs Market Growth?
North America was the largest region in the hepatocellular carcinoma drug market in 2024. The regions covered in the hepatocellular carcinoma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Hepatocellular Carcinoma Drugs Market?
2. What is the CAGR expected in the Hepatocellular Carcinoma Drugs Market?
3. What Are the Key Innovations Transforming the Hepatocellular Carcinoma Drugs Industry?
4. Which Region Is Leading the Hepatocellular Carcinoma Drugs Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rising Occurrence Of Hepatocellular Carcinoma Fuels Growth In The Hepatocellular Carcinoma Drug Market: Key Factor Driving The Growth In The Hepatocellular Carcinoma Drugs Market here
News-ID: 3992235 • Views: …
More Releases from The Business Research Company
Foam Tape Industry to Achieve $14.62 Billion Growth by 2029
Get 30% off global market reports with code ONLINE30 and keep ahead of tariffs, macro trends, and worldwide economic developments.
How Will the Foam Tape Market Grow by 2025 in Terms of Size and Growth?
In recent times, there has been significant growth in the market size for foam tape. It is projected to escalate from $10.02 billion in 2024 to $10.77 billion in 2025, demonstrating a compound annual growth rate (CAGR)…
Continuous Positive Airway Pressure (CPAP) Mask Market Expansion Outlook: $3.85 …
Get 30% off global market reports with code ONLINE30 and keep ahead of tariffs, macro trends, and worldwide economic developments.
What Is the Projected CAGR for the Continuous Positive Airway Pressure (CPAP) Mask Market from 2024 to 2025?
In recent times, the market size of the continuous positive airway pressure (cpap) mask has seen robust growth. The market is projected to rise from $2.83 billion in 2024 to $3 billion in 2025,…
Alkyd Coating Market to Record 7.5% CAGR Growth Through 2029 | Global Analysis R …
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
Alkyd Coating Market Outlook: How is the Market Expected to Grow by 2025?
The market size of alkyd coatings has experienced significant growth in the past few years. The market is projected to expand from $25.13 billion in 2024 to $26.74 billion in 2025, exhibiting a compound annual growth rate…
Water Free Skincare Market Analysis: $22.5 Billion by 2029 With a CAGR of 7%
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
Water Free Skincare Market Value Projection: How Much Will the Market Size by 2025?
The market size of waterless skincare has experienced a robust increase in recent years. The expected growth is from $15.96 billion in 2024 to $17.15 billion in 2025, with a compound annual growth rate (CAGR) of 7.5%.…
More Releases for Hepatocellular
Laboratory-Produced Molecule In The Hepatocellular Carcinoma Drugs Market Indust …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Hepatocellular Carcinoma Drugs Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for drugs used in hepatocellular carcinoma has seen significant expansion in the past few years. The market, which is predicted to rise from $1.16 billion in 2024 to $1.27 billion in…
Hepatocellular Carcinoma Pipeline 2024
DelveInsight, "Hepatocellular Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample and discover the recent…
Hepatocellular Carcinoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Hepatocellular Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Hepatocellular…
Hepatocellular Carcinoma Market - Winning the Battle Against Hepatocellular: Bre …
Newark, New Castle, USA: The "Hepatocellular Carcinoma Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Hepatocellular Carcinoma Market: https://www.growthplusreports.com/report/hepatocellular-carcinoma-market/8027
This latest report researches the industry structure, sales, revenue,…
Hepatocellular Carcinoma Market Insights, Forecast to 2030
The report extensively examines the global Hepatocellular Carcinoma market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Hepatocellular Carcinoma . For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers influencing the global market…
Hepatocellular Carcinoma Drugs Market Opportunity Analysis, 2018-2026
Hepatocellular carcinoma (HCC) is a major type of primary liver cancer that arises from the liver cells or hepatocytes. The disease is found to occur mainly in patients with hepatitis B, hepatitis C, cirrhosis, obesity, and diabetes. Diagnosis of hepatocellular carcinoma is mainly done by imaging tests such as ultrasound, MRI, CT scan, and liver biopsy. Treatment for hepatocellular carcinoma mainly includes radiation therapy, ablation therapy in addition to chemotherapy…
